Table 2.
Disease activity of AAV patients with ENT involvement with or without S. aureus colonization
| Disease activity | S. aureus colonization | P value | |
|---|---|---|---|
| Yes n = 44 | No n = 56 | ||
| Systemic symptoms | |||
| History of one or more relapses, n (%) | 23 (54.8%) | 34 (64.2%) | 0.354 |
| Relapse number per patient years, median (IQR) | 0.09 (0–0.18) | 0.12 (0–0.29) | 0.191 |
| BVAS3 score at last visit, median (IQR) | 1 (0–4) | 0 (0–4) | 0.876 |
| Local symptoms | |||
| History of one or more ENT relapses, n (%)a | 15 (50.0%) | 25 (59.5%) | 0.423 |
| Development of saddle nose deformity during follow-up, n (%)a | 4 (11.4%) | 3 (6.4%) | 0.419 |
Values are median (interquartile range IQR) or n (%)
AAV ANCA-associated vasculitis, ANCA anti-neutrophilic cytoplasmic autoantibody, BVAS3 Birmingham vasculitis activity score version 3, ENT ear nose and throat
aMore than 10% missing in analysis. For an overview of the number of included patients per analysis, see supplementary table A